毒品管理局被控在法庭上撒谎,声称MMJ BioPharma缺乏有效的药物供应协议,尽管有证据。 DEA accused of lying in court, claiming MMJ BioPharma lacks valid drug supply agreement despite evidence.

缉毒局被指控在法庭上对MMJ BioPharma植物种植案撒谎,声称该公司与注册的毒品制造商没有有效的供货协议,尽管有证据表明签署了一项符合所有管制要求的协议。 The DEA is accused of lying in court about MMJ BioPharma Cultivation, stating the company had no valid supply agreement with a registered drug manufacturer, despite evidence of a signed agreement meeting all regulatory requirements. 此案质疑缉毒局遵守法律及其对大麻医学研究的承诺。 This case questions the DEA's adherence to the law and its commitment to medical marijuana research. 促请新的缉毒署署长Terrance Cole处理这些索赔要求,并可能允许MMJ的临床试验进行。 New DEA Administrator Terrance Cole is urged to address these claims and possibly allow MMJ's clinical trials to proceed.